Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Total Liabilities (2021 - 2025)

Valion Bio has reported Total Liabilities over the past 5 years, most recently at $7.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 2635.29% year-over-year to $7.4 million; the TTM value through Dec 2025 reached $7.4 million, up 2635.29%, while the annual FY2025 figure was $7.4 million, 2635.29% up from the prior year.
  • Total Liabilities for Q4 2025 was $7.4 million at Valion Bio, up from $638000.0 in the prior quarter.
  • Over five years, Total Liabilities peaked at $7.4 million in Q4 2025 and troughed at $272000.0 in Q4 2024.
  • A 5-year average of $2.1 million and a median of $1.6 million in 2022 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: crashed 82.75% in 2024 and later surged 2635.29% in 2025.
  • Year by year, Total Liabilities stood at $1.8 million in 2021, then rose by 27.27% to $2.2 million in 2022, then decreased by 29.76% to $1.6 million in 2023, then crashed by 82.75% to $272000.0 in 2024, then surged by 2635.29% to $7.4 million in 2025.
  • Business Quant data shows Total Liabilities for TIVC at $7.4 million in Q4 2025, $638000.0 in Q3 2025, and $821000.0 in Q2 2025.